APPLICATIONS PUBLISHED 28 AUGUST 2002
Published: 1-Feb-2003
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Nitric oxide donors for inducing neurogenesis
Henry Ford Health System 1233670*
Compsns and methods for drug delivery using amphiphile binding molecules
Mirus Corp 1233671*
Sustained percutaneous delivery of a biologically active substance
Advanced Research and Technology Institute 1233751*
Radiation sensitive liposomes
The Arizona Board of Regents on behalf of the University of Arizona 1233752*
Compsn and methods for the treatment of otitis media
Scientific Development and Research 1233753*
Targeted drug delivery with a CD44 receptor ligand
The Regents of the University of California 1233754*
Hydrolysed cellulose granulations of salts of drugs
R. P. Scherer Technologies 1233755*
Solid carriers for improved delivery of active ingredients in pharmaceutical compsns
Lipocine 1233756*
Aerosol compsn comprising formoterol
Novartis 1233757*
Orally administrable pharmaceutical product and method of fabrication thereof
Psimedica 1233760*
Osmotic dosage form comprising first and second coats
Alza Corp 1233761*
Patch therapeutic agent delivery device having texturised backing
3M Innovative Properties Company 1233762*
Transdermal therapeutic systems with improved stability and a method for the production thereof
LTS Lohmann Therapie-Systeme 1233763*
Transdermal device comprising a reservoir and a matrix containing the same active principle
Pierre Fabre Medicament 1233764*
Treatment of eosinophil associated pathologies by modulating PKC-(d) activity
Mayo Foundation for Medical Research; Regents of the University of Minnesota 1233765*
Use of synergistic combinations of a NK1? receptor antagonist and a GABA analogue in psychiatric disorders
Warner-Lambert 1233766*
Pyruvate ester compsn and method of use for resuscitation after events of ischaemia and reperfusion
Xamthus Life Sciences; Beth Israel Deaconess Medical Centre 1233767*
Carvediol methanesulphonate
SmithKline Beecham 1233768*
Novel compounds
SmithKline Beecham 1233769*
Phosphonate compounds
The Regents of the University of California at San Diego 1233770*
Protease inhibitors
SmithKline Beecham 1233771*
Boron compounds and complexes as anti-inflammatory agents
Topgene 1233772*
Mixture of pomegranate seed oil and juice products
Rimonest 1233773*
Urotensin-II analogues
SmithKline Beecham 1233774*
Tyrosine- and tryptophan-containing peptides as antioxidants
Max-Planck-Gesellschaft zur Foerderung der Wissenschaft 1233775*
Urotensin-II cyclic analogues
SmithKline Beecham 1233776*
Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies
Human Genome Sciences 1233777*
Stanniocalcin proteins and nucleic acids and methods based thereon
Human Genome Sciences; University of Helsinki 1233778*
New uses of suppressive macrophage activation factors
Innogenetics 1233779*
Identification of sortase gene
The Regents of the University of California 1233780*
Assays and therapeutics for latent viral infection
Oklahoma Medical Research Foundation 1233781*
Eliciting HCV-specific antibodies
Chiron 1233782*
HBV/HCV virus-like particle
Chiron 1233783*
Compsns and methods for stabilising biological molecules upon lyophilisation
Chiron 1233784*
'Bonzo' chemokine receptor antibodies and ligands
Millennium Pharmaceuticals 1233785*
Product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance
Societe de Conseils de Recherches et d'Applications Scientifiques 1233786*
Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
Societe de Conseils de Recherches et d'Applications Scientifiques 1233787*
Compsn for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl L-carnitine and chitosan
Sigma-Tau Healthscience 1233788*
Prodrugs of chemotherapeutic agents with oxaalkanoic acids
University of Kentucky Research Foundation 1233789*
A33 antigen specific immunoglobulin products in cancer therapy
Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Centre; The Scripps Research Institute 1233790*
Methods of treating lupus based in antibody affinity and screening methods and compsns
La Jolla Pharmaceutical Company 1233791*
Preparation of 3-substituted-4-aryl-quinolin-2-one derivatives
Bristol-Myers Squibb 1233947*
Stable polymorph of N-(3-ethynyl-phenylamino)-6,7-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
OSI Pharmaceuticals 1233948*
5-substituted arylpyrimidines
Neurogen 1233949*
3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/P39 kinase inhibitors
SmithKline Beecham 1233950*
Novel benzothiadiazine derivatives, preparation methods and pharmaceutical compsns containing same
Les Laboratoires Servier 1233953*
A process for the preparation of 2,4-(alpha-phenyl-P-chlorobenzyl) piperazin-1-yl) ethoxy acetic acid and novel intermediates therefor
Egis Gyogysergyar 1233954*
Process for preparing piperazine-substituted aliphatic carboxylates
Salsbury Chemicals 1233955*
